Text this: Efficacy and safety of first-line necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin in East Asian patients with stage IV squamous non-small cell lung cancer: A subgroup analysis of the phase 3, open-label, randomized SQUIRE study

  _  _    __   __  __    __   __   __   _    _   
 | \| ||  \ \\/ // \ \\ / //  \ \\/ // | |  | || 
 |  ' ||   \ ` //   \ \/ //    \ ` //  | |/\| || 
 | .  ||    | ||     \  //      | ||   |  /\  || 
 |_|\_||    |_||      \//       |_||   |_// \_|| 
 `-` -`     `-`'       `        `-`'   `-`   `-`